<?xml version='1.0' encoding='utf-8'?>
<document id="31167814"><sentence text="Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir." /><sentence text="Glecaprevir and pibrentasvir are oral direct-acting antiviral agents approved in combination for treatment of chronic hepatitis C viral infection"><entity charOffset="0-11" id="DDI-PubMed.31167814.s2.e0" text="Glecaprevir" /><entity charOffset="16-28" id="DDI-PubMed.31167814.s2.e1" text="pibrentasvir" /><pair ddi="false" e1="DDI-PubMed.31167814.s2.e0" e2="DDI-PubMed.31167814.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31167814.s2.e0" e2="DDI-PubMed.31167814.s2.e1" /></sentence><sentence text=" In vitro studies identified the combination as potentially clinically relevant inhibitors of the efflux transporters P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and the hepatic uptake transporters organic anion transporting polypeptide (OATP) 1B1 and OATP1B3" /><sentence text=" Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0" /><sentence text="33, 2" /><sentence text="3, 0" /><sentence text="017, and 0" /><sentence text="064 µM, respectively" /><sentence text=" Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0" /><sentence text="036, 14, and 1" /><sentence text="3 µM, respectively" /><sentence text=" Neither agent inhibited organic cation transporter (OCT) 1, OCT2, organic anion transporter (OAT) 1, OAT3, multidrug and toxin extrusion (MATE) 1, or MATE2K" /><sentence text=" Open-label phase 1 clinical drug-drug interaction studies were conducted in healthy subjects to evaluate interaction potential of glecaprevir/pibrentasvir and coadministered selective substrates for P-gp (digoxin, dabigatran etexilate, and sofosbuvir), BCRP (rosuvastatin and sofosbuvir), and OATP1B1/3 (pravastatin and rosuvastatin)"><entity charOffset="215-235" id="DDI-PubMed.31167814.s13.e0" text="dabigatran etexilate" /><entity charOffset="241-251" id="DDI-PubMed.31167814.s13.e1" text="sofosbuvir" /><entity charOffset="254-258" id="DDI-PubMed.31167814.s13.e2" text="BCRP" /><entity charOffset="260-272" id="DDI-PubMed.31167814.s13.e3" text="rosuvastatin" /><entity charOffset="277-287" id="DDI-PubMed.31167814.s13.e4" text="sofosbuvir" /><entity charOffset="294-301" id="DDI-PubMed.31167814.s13.e5" text="OATP1B1" /><entity charOffset="305-316" id="DDI-PubMed.31167814.s13.e6" text="pravastatin" /><entity charOffset="321-333" id="DDI-PubMed.31167814.s13.e7" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e0" e2="DDI-PubMed.31167814.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e1" e2="DDI-PubMed.31167814.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e1" e2="DDI-PubMed.31167814.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e1" e2="DDI-PubMed.31167814.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e1" e2="DDI-PubMed.31167814.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e1" e2="DDI-PubMed.31167814.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e1" e2="DDI-PubMed.31167814.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e1" e2="DDI-PubMed.31167814.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e2" e2="DDI-PubMed.31167814.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e2" e2="DDI-PubMed.31167814.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e2" e2="DDI-PubMed.31167814.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e2" e2="DDI-PubMed.31167814.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e2" e2="DDI-PubMed.31167814.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e2" e2="DDI-PubMed.31167814.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e3" e2="DDI-PubMed.31167814.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e3" e2="DDI-PubMed.31167814.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e3" e2="DDI-PubMed.31167814.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e3" e2="DDI-PubMed.31167814.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e3" e2="DDI-PubMed.31167814.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e4" e2="DDI-PubMed.31167814.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e4" e2="DDI-PubMed.31167814.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e4" e2="DDI-PubMed.31167814.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e4" e2="DDI-PubMed.31167814.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e5" e2="DDI-PubMed.31167814.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e5" e2="DDI-PubMed.31167814.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e5" e2="DDI-PubMed.31167814.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e6" e2="DDI-PubMed.31167814.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s13.e6" e2="DDI-PubMed.31167814.s13.e7" /></sentence><sentence text=" The pharmacokinetic maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) parameters were evaluated for probe substrates alone and in combination with glecaprevir/pibrentasvir"><entity charOffset="184-195" id="DDI-PubMed.31167814.s14.e0" text="glecaprevir" /><entity charOffset="196-208" id="DDI-PubMed.31167814.s14.e1" text="pibrentasvir" /><pair ddi="false" e1="DDI-PubMed.31167814.s14.e0" e2="DDI-PubMed.31167814.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31167814.s14.e0" e2="DDI-PubMed.31167814.s14.e1" /></sentence><sentence text=" The Cmax central values increased by 72%, 105%, 123%, 462%, and 66% for digoxin, dabigatran, pravastatin, rosuvastatin, and sofosbuvir, respectively, and the AUC central values increased by 48%, 138%, 130%, 115%, and 125% for digoxin, dabigatran, pravastatin, rosuvastatin, and sofosbuvir, respectively"><entity charOffset="73-80" id="DDI-PubMed.31167814.s15.e0" text="digoxin" /><entity charOffset="82-92" id="DDI-PubMed.31167814.s15.e1" text="dabigatran" /><entity charOffset="94-105" id="DDI-PubMed.31167814.s15.e2" text="pravastatin" /><entity charOffset="107-119" id="DDI-PubMed.31167814.s15.e3" text="rosuvastatin" /><entity charOffset="125-135" id="DDI-PubMed.31167814.s15.e4" text="sofosbuvir" /><entity charOffset="227-234" id="DDI-PubMed.31167814.s15.e5" text="digoxin" /><entity charOffset="236-246" id="DDI-PubMed.31167814.s15.e6" text="dabigatran" /><entity charOffset="248-259" id="DDI-PubMed.31167814.s15.e7" text="pravastatin" /><entity charOffset="261-273" id="DDI-PubMed.31167814.s15.e8" text="rosuvastatin" /><entity charOffset="279-289" id="DDI-PubMed.31167814.s15.e9" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e0" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e1" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e2" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e3" e2="DDI-PubMed.31167814.s15.e3" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e3" e2="DDI-PubMed.31167814.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e3" e2="DDI-PubMed.31167814.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e3" e2="DDI-PubMed.31167814.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e3" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e3" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e3" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e4" e2="DDI-PubMed.31167814.s15.e4" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e4" e2="DDI-PubMed.31167814.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e4" e2="DDI-PubMed.31167814.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e4" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e4" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e4" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e5" e2="DDI-PubMed.31167814.s15.e5" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e5" e2="DDI-PubMed.31167814.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e5" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e5" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e5" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e6" e2="DDI-PubMed.31167814.s15.e6" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e6" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e6" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e6" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e7" e2="DDI-PubMed.31167814.s15.e7" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e7" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e7" e2="DDI-PubMed.31167814.s15.e9" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e8" e2="DDI-PubMed.31167814.s15.e8" /><pair ddi="false" e1="DDI-PubMed.31167814.s15.e8" e2="DDI-PubMed.31167814.s15.e9" /></sentence><sentence text=" Exposure of sofosbuvir metabolite GS-331007 (nucleoside analog) was similar with or without glecaprevir/pibrentasvir"><entity charOffset="13-23" id="DDI-PubMed.31167814.s16.e0" text="sofosbuvir" /><entity charOffset="35-44" id="DDI-PubMed.31167814.s16.e1" text="GS-331007" /><entity charOffset="105-117" id="DDI-PubMed.31167814.s16.e2" text="pibrentasvir" /><pair ddi="false" e1="DDI-PubMed.31167814.s16.e0" e2="DDI-PubMed.31167814.s16.e0" /><pair ddi="false" e1="DDI-PubMed.31167814.s16.e0" e2="DDI-PubMed.31167814.s16.e1" /><pair ddi="false" e1="DDI-PubMed.31167814.s16.e0" e2="DDI-PubMed.31167814.s16.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s16.e1" e2="DDI-PubMed.31167814.s16.e1" /><pair ddi="false" e1="DDI-PubMed.31167814.s16.e1" e2="DDI-PubMed.31167814.s16.e2" /></sentence><sentence text=" The outcomes of the clinical drug-drug interaction studies confirmed clinically relevant inhibition of P-gp, BCRP, and OATP1B1/3, and were used to provide dosing guidance for the concomitant use of glecaprevir/pibrentasvir with relevant transporter substrates"><entity charOffset="199-210" id="DDI-PubMed.31167814.s17.e0" text="glecaprevir" /><entity charOffset="211-223" id="DDI-PubMed.31167814.s17.e1" text="pibrentasvir" /><entity charOffset="110-121" id="DDI-PubMed.31167814.s17.e2" text="BCRP" /><pair ddi="false" e1="DDI-PubMed.31167814.s17.e2" e2="DDI-PubMed.31167814.s17.e2" /><pair ddi="false" e1="DDI-PubMed.31167814.s17.e2" e2="DDI-PubMed.31167814.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31167814.s17.e2" e2="DDI-PubMed.31167814.s17.e1" /><pair ddi="false" e1="DDI-PubMed.31167814.s17.e0" e2="DDI-PubMed.31167814.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31167814.s17.e0" e2="DDI-PubMed.31167814.s17.e1" /></sentence><sentence text="" /></document>